<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-8-309</article-id><article-id pub-id-type="pmid">18950515</article-id><article-id pub-id-type="doi">10.1186/1471-2407-8-309</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Toyama</surname><given-names>Tatsuya</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>toyamat-ncu@umin.ac.jp</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Yamashita</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hirokoy@med.nagoya-cu.ac.jp</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kondo</surname><given-names>Naoto</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nao0613@med.nagoya-cu.ac.jp</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Okuda</surname><given-names>Katsuhiro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kokuda@med.nagoya-cu.ac.jp</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Takahashi</surname><given-names>Satoru</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>sattak@med.nagoya-cu.ac.jp</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Sasaki</surname><given-names>Hidefumi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hisasaki@med.nagoya-cu.ac.jp</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Sugiura</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hsugiura@med.nagoya-cu.ac.jp</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Iwase</surname><given-names>Hirotaka</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>hiwase@kumamoto-u.ac.jp</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Fujii</surname><given-names>Yoshitaka</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yosfujii@med.nagoya-cu.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan</aff><aff id="I2"><label>2</label>Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan</aff><aff id="I3"><label>3</label>Division of Pathology, Nagoya City University Hospital, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan</aff><aff id="I4"><label>4</label>Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>25</day><month>10</month><year>2008</year></pub-date><volume>8</volume><fpage>309</fpage><lpage>309</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/309"/><history><date date-type="received"><day>15</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Toyama et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Toyama et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Toyama Tatsuya toyamat-ncu@umin.ac.jp </dc:author><dc:title> Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Cancer 8(1): 309-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2008)8:1&#x0003c;309&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins.</p></sec><sec sec-type="methods"><title>Methods</title><p>We studied 969 consecutive Japanese patients diagnosed with invasive breast cancer from January 1981 to December 2003, and selected TNBCs based on the immunohistochemical data. Analyses of epidermal growth factor receptor (<italic>EGFR</italic>) gene mutations and amplification, and <italic>BRCA</italic>1 mRNA expression were performed on these samples using TaqMan PCR assays. The prognostic significance of TNBCs was also explored. Median follow-up was 8.3 years.</p></sec><sec><title>Results</title><p>A total of 110 (11.3%) patients had TNBCs in our series. Genotyping of the <italic>EGFR </italic>gene was performed to detect 14 known <italic>EGFR </italic>mutations, but none was identified. However, <italic>EGFR </italic>gene copy number was increased in 21% of TNBCs, while only 2% of ER- and PgR-positive, HER2-negative tumors showed slightly increased <italic>EGFR </italic>gene copy numbers. Thirty-one percent of TNBCs stained positive for EGFR protein by immunohistochemistry. <italic>BRCA1 </italic>mRNA expression was also decreased in TNBCs compared with controls. Triple negativity was significantly associated with grade 3 tumors, TP53 protein accumulation, and high Ki67 expression. TNBC patients had shorter disease-free survival than non-TNBC in node-negative breast cancers.</p></sec><sec><title>Conclusion</title><p>TNBCs have an aggressive clinical course, and <italic>EGFR </italic>and <italic>BRCA1 </italic>might be candidate therapeutic targets in this disease.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Although the overall mortality due to breast cancer in the United States has decreased, attributed in part to breast screening and early application of various treatments, overall mortality in Japan is still increasing [<xref ref-type="bibr" rid="B1">1</xref>]. Breast cancers represent a heterogeneous group of tumors that are diverse in behavior, outcome, and sensitivity to therapy. To reduce mortality from breast cancer, it would be desirable to identify and characterize tumors having a poor prognosis. Emerging data demonstrate that stratification of tumors by gene expression profiles divides breast cancer into four common subtypes which are associated with different clinical outcome [<xref ref-type="bibr" rid="B2">2</xref>]. Two of them are estrogen receptor (ER)-positive (luminal and luminal/HER2+) and two are ER-negative (basal-like and HER2 positive) [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Although the immunohistochemical staining profile can be a useful surrogate for gene expression analysis, the optimum immunohistochemical profile of the basal-like subtype remains unclear. However, the basal-like category is composed almost entirely of triple-negative breast cancers (TNBCs) (i.e., tumors lacking ER, progesterone receptor (PgR) and HER2 expression) [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. A simplified method of classification, based on immunohistochemical assays for ER, PgR, and HER2, is clinically useful, and clinicians are increasingly taking triple-negative status into account in clinical decision-making and therapeutic protocol design. Epidermal growth factor receptor (EGFR) is more frequently expressed in TNBCs than in non-TNBCs [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, the EGFR is considered a candidate treatment target for TNBCs.</p><p>Cluster analyses of microarray expression profiling data have shown that familial <italic>BRCA1 </italic>mutant tumors tend to fall into the basal-like category [<xref ref-type="bibr" rid="B2">2</xref>]. Some studies have indicated that <italic>BRCA1 </italic>mRNA expression is lower in basal-like sporadic cancers [<xref ref-type="bibr" rid="B8">8</xref>], and in approximately 30% of sporadic breast cancers [<xref ref-type="bibr" rid="B9">9</xref>]. It is believed that this may be the result of an epigenetic mechanism acting on the <italic>BRCA1 </italic>gene or a dysfunction in the upstream pathways regulating <italic>BRCA1 </italic>expression [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. These sporadic tumors with reduced <italic>BRCA</italic>1 expression tend to be triple-negative, and remarkably similar to <italic>BRCA1</italic>-mutated tumors [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Here, we present data on a large series of TNBCs with long-term follow-up and data on the status of their <italic>EGFR </italic>and <italic>BRCA1 </italic>genes.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>A total of 969 surgically resected breast carcinomas with tissue blocks available were selected from the archive of the Department of Breast and Endocrine Surgery, Nagoya City University Hospital in Japan. Specimens were obtained from patients who underwent surgery between January 1981 and December 2003. Tissues were fixed in 10% buffered formalin and embedded in paraffin or placed in liquid nitrogen immediately after resection and stored at -80&#x000b0;C until DNA and RNA extraction. Informed consent was obtained before the surgery. The histological grade was estimated according to the Bloom and Richardson method proposed by Elston and Ellis [<xref ref-type="bibr" rid="B11">11</xref>]. Analysis of clinical outcome was performed in a total of 557 consecutive breast cancer patients operated from January 1981 to December 1999, because their clinicopathological and survival data were available for this study. Disease-free survival (DFS) was defined as the interval from the date of primary surgery to the first locoregional recurrence or distant metastasis. The distant disease-free survival (DDFS) was defined as the interval from the date of primary surgery to the identification of distant metastasis. The median follow-up period was 8.3 years (range 3 to 281 months). Relapse data were available in 543 of 557 patients examined: 159 (28.5%) experienced disease recurrence; 99 (17.7%) showed distant relapse; and 75 (13.4%) had died. This protocol was approved by the Institutional Review Board of Nagoya City University Graduate School of Medical Sciences.</p></sec><sec><title>DNA and RNA extraction</title><p>Genomic DNA and total RNA from homogeneous microscopically confirmed breast cancer tissues was isolated from approximately 500 mg of each frozen specimen using a phenol-chloroform extraction method for DNA extraction, and with TRIZOL reagent (Invitrogen Japan K.K., Tokyo, Japan) for RNA extraction according to the manufacturer's recommendations. Total RNA was also isolated from MCF-7 cells with TRIZOL reagent (Invitrogen).</p></sec><sec><title>Immunohistochemical analysis</title><p>One 4-&#x003bc;m section from each paraffin block specimen was first stained with hematoxylin and eosin in order to ascertain that an adequate number of invasive ductal carcinoma cells were present and that quality of fixation was adequate for immunohistochemical analysis. Serial sections (4-&#x003bc;m) were then prepared from suitable blocks and float-mounted on adhesive-coated glass slides for ER&#x003b1;, PgR, HER2, TP53, Ki67, cytokeratin (CK) 5/6, CK14 and EGFR staining. Primary antibodies were mouse monoclonal anti-human antibodies against ER&#x003b1; (1D5; DAKO, Glostrup, Denmark) at a 1:100 dilution, PgR (PgR636; DAKO) at a 1:100 dilution, TP53 (PAb1801; Novocastra, Newcastle, UK) at 1:50, Ki67 (MIB-1; DAKO) at 1:100, CK5/6 (D5/16 B4; DAKO) at 1:50 and CK14 (LL002; NeoMarkers, Fremont, CA) at 1:200. Rabbit anti-human c-erbB2 oncoprotein antibody (DAKO) at a 1:200 dilution was used for HER2. The DAKO EnVision system (DAKO EnVision-labeled polymer, peroxidase) was used for detection of ER&#x003b1;, PgR, HER2, Ki67, CK5/6, and CK14. The streptavidin-biotin system (SAB-PO kit; Nichirei Co., Inc., Tokyo, Japan) was applied for detection of the bound TP53 antibody. Immunostaining for EGFR was performed using the EGFRpharmDx assay detection system (prediluted; DAKO).</p></sec><sec><title>Interpretation of immunohistochemical staining</title><p>Immunostained specimens were scored after the entire slide had been evaluated by light microscopy. The expression of ER&#x003b1; was scored by assigning a proportion score and an intensity score according to Allred's procedure [<xref ref-type="bibr" rid="B12">12</xref>]. Any brown nuclear staining in invasive breast epithelium was counted toward the proportion score. Tumors with scores of 3 or greater were considered to be positive for ER&#x003b1; expression. HER2 immunostaining was evaluated using the same method as is employed by the HercepTest (DAKO). To determine the score of HER2 expression the membrane staining pattern was estimated and scored on a scale of 0 to 3+. Tumors with scores of 0 and 1 were considered to be negative, and tumors with a score of 3 were considered to be positive for HER2 overexpression. All tumors with a score of 2 were omitted from the analysis in this study because fluorescent <italic>in situ </italic>hybridization (FISH) analysis was not carried out on them. In the case of TP53, tumors were considered immunohistochemically positive when &#x02265; 10% of the tumor cells showed nuclear staining [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. The expression status of Ki67 was assessed according to the estimated proportion of nuclear staining of tumor cells that were positively stained. Scoring criteria for Ki67 were as follows (in the form proportion of nuclear staining = score): none = 0, &#x0003c;1/100 = 1, 1/100-1/10 = 2, 1/10-1/2 = 3, and &#x0003e;1/2 = 4 [<xref ref-type="bibr" rid="B15">15</xref>]. Tumors with a score of <underline>3</underline> or greater for Ki67 were considered to have high Ki67 expression. Positivity for CK5/6 and CK14 was defined as the detection of more than 5% of invasive tumor cells showing strong cytoplasmic and membrane staining [<xref ref-type="bibr" rid="B16">16</xref>]. Immunostaining for EGFR was interpreted as positive when at least 10% of tumor cells showed strong membrane staining [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Genetic analysis of EGFR</title><p>The primers and TaqMan probes were designed for 14 known mutations in the <italic>EGFR </italic>gene [<xref ref-type="bibr" rid="B18">18</xref>]. TaqMan genotyping assays for <italic>EGFR </italic>mutations were performed on Applied Biosystems 7500 Fast Real-Time PCR equipment (Applied Biosystems) as described previously [<xref ref-type="bibr" rid="B18">18</xref>]. The results were analyzed using the allelic discrimination assay program [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Real-Time Reverse Transcription (RT)-PCR</title><p>RT was performed as described previously [<xref ref-type="bibr" rid="B22">22</xref>]. Real-time quantitative RT-PCR of the <italic>BRCA1 </italic>gene was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) in the Applied Biosystems 7500 Fast Real-Time PCR System, following the manufacturer's instructions. The primers and probes for the <italic>BRCA1 </italic>mRNA expression assay are commercially available (TaqMan Gene Expression Assays, Assay ID: Hs00173233_m1, Applied Biosystems). The PCR conditions were as follows: initial denaturation at 95&#x000b0;C for 2 sec, followed by 40 cycles of 95&#x000b0;C for 3 sec, and 60&#x000b0;C for 30 sec. To ensure the fidelity of mRNA extraction and reverse transcription, <italic>BRCA1 </italic>signals from all samples were normalized against <italic>GAPDH </italic>as an internal control. The primers and probes for <italic>GAPDH </italic>mRNA expression assay are commercially available (TaqMan Gene Expression Assays, Assay ID: Hs99999905_m1, Applied Biosystems). The PCR conditions for amplification of <italic>GAPDH </italic>were as follows: initial denaturation at 95&#x000b0;C for 2 sec, followed by 40 cycles of 95&#x000b0;C for 3 sec, and 60&#x000b0;C for 30 sec. For each PCR run, a standard curve was constructed with serial dilutions of cDNA obtained from MCF-7 cells, which express <italic>BRCA1 </italic>mRNA.</p></sec><sec><title>Statistical analyses</title><p>All molecular and immunohistochemical analyses were performed blinded to clinical data. Statistical calculations were performed with StatView-J 5.0 software (SAS Institute Inc., Cary, NC). The relationship between the frequency of TNBC or non-TNBC and clinicopathologic factors were assessed by &#x003c7;<sup>2 </sup>and Fisher's exact probability tests. The Mann-Whitney U-test was performed for the analyses of the <italic>EGFR </italic>gene copy number and <italic>BRCA1 </italic>mRNA expression. DFS and DDFS curves were generated by the Kaplan-Meier method and verified by the log-rank test. Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. Differences were considered significant when a <italic>P </italic>value &#x0003c; 0.05 was obtained.</p></sec></sec><sec><title>Results</title><sec><title>Patient Characteristics and Immunohistochemical results</title><p>In total, 969 Japanese cases of invasive breast cancer undergoing surgery at Nagoya City University Hospital from January 1981 to December 2003 were informative for the 3 markers ER, PgR, and HER2. Of these informative cases, 110 (11.3%) were found to be TNBCs. Immunohistological analyses of TP53 and Ki67, and clinicopathological analysis were performed in 531 consecutive patients from 1981 to 1999. Table <xref ref-type="table" rid="T1">1</xref> shows the features of 71 TNBCs compared with 415 non-TNBCs concerning different clinicopathological variables and biomarkers. All tumors with a HER2 score 2+ were omitted from this analysis, as indicated in Methods. TNBC was significantly associated with grade 3 tumors (P &#x0003c; 0.0001), with TP53 protein accumulation (P &#x0003c; 0.0001) and with high Ki67 expression (P &#x0003c; 0.0001), as well as lymph node status (P = 0.02).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of Patients with Different Tumor Subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Variables</bold></td><td align="center" colspan="2"><bold>Total</bold></td><td align="center" colspan="2"><bold>Triple negative</bold></td><td align="center" colspan="2"><bold>Non-triple negative</bold></td><td align="center"><bold>P value</bold></td></tr><tr><td></td><td colspan="6"><hr></hr></td><td></td></tr><tr><td></td><td align="center" colspan="2"><bold><italic>N = 486 (100%)</italic></bold></td><td align="center" colspan="2"><bold><italic>N = 71 (15%)</italic></bold></td><td align="center" colspan="2"><bold><italic>N = 415 (85%)</italic></bold></td><td></td></tr><tr><td></td><td align="center"><bold><italic>No.</italic></bold></td><td align="center"><bold><italic>%</italic></bold></td><td align="center"><bold><italic>No.</italic></bold></td><td align="center"><bold><italic>%</italic></bold></td><td align="center"><bold><italic>No.</italic></bold></td><td align="center"><bold><italic>%</italic></bold></td><td></td></tr></thead><tbody><tr><td align="left">Age, years</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">0.49</td></tr><tr><td align="left">&#x02003;&#x02264;50</td><td align="center">198</td><td align="center">41</td><td align="center">32</td><td align="center">44</td><td align="center">166</td><td align="center">40</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;50</td><td align="center">288</td><td align="center">59</td><td align="center">39</td><td align="center">56</td><td align="center">249</td><td align="center">60</td><td></td></tr><tr><td align="left">Size</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">0.23</td></tr><tr><td align="left">&#x02003;&#x02264;2 cm</td><td align="center">181</td><td align="center">37</td><td align="center">21</td><td align="center">30</td><td align="center">160</td><td align="center">39</td><td></td></tr><tr><td align="left">&#x02003;&#x0003e;2 cm</td><td align="center">288</td><td align="center">59</td><td align="center">46</td><td align="center">65</td><td align="center">242</td><td align="center">58</td><td></td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">17</td><td></td><td align="center">4</td><td align="center">5</td><td align="center">13</td><td align="center">3</td><td></td></tr><tr><td align="left">Nodal status</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">0.02</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">275</td><td align="center">57</td><td align="center">48</td><td align="center">68</td><td align="center">227</td><td align="center">55</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">192</td><td align="center">40</td><td align="center">19</td><td align="center">27</td><td align="center">173</td><td align="center">42</td><td></td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">19</td><td align="center">3</td><td align="center">4</td><td align="center">5</td><td align="center">15</td><td align="center">3</td><td></td></tr><tr><td align="left">Histology</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">0.14</td></tr><tr><td align="left">&#x02003;Ductal</td><td align="center">454</td><td align="center">94</td><td align="center">66</td><td align="center">93</td><td align="center">388</td><td align="center">93</td><td></td></tr><tr><td align="left">&#x02003;Lobular</td><td align="center">16</td><td align="center">3</td><td align="center">0</td><td align="center">0</td><td align="center">16</td><td align="center">4</td><td></td></tr><tr><td align="left">&#x02003;Other</td><td align="center">16</td><td align="center">3</td><td align="center">5</td><td align="center">7</td><td align="center">11</td><td align="center">3</td><td></td></tr><tr><td align="left">Grade</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;1</td><td align="center">92</td><td align="center">19</td><td align="center">4</td><td align="center">6</td><td align="center">88</td><td align="center">21</td><td></td></tr><tr><td align="left">&#x02003;2</td><td align="center">273</td><td align="center">56</td><td align="center">32</td><td align="center">45</td><td align="center">241</td><td align="center">58</td><td></td></tr><tr><td align="left">&#x02003;3</td><td align="center">101</td><td align="center">21</td><td align="center">34</td><td align="center">48</td><td align="center">67</td><td align="center">16</td><td></td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">20</td><td align="center">4</td><td align="center">1</td><td align="center">1</td><td align="center">19</td><td align="center">5</td><td></td></tr><tr><td align="left">TP53 expression</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">392</td><td align="center">81</td><td align="center">43</td><td align="center">61</td><td align="center">349</td><td align="center">84</td><td></td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">92</td><td align="center">19</td><td align="center">28</td><td align="center">39</td><td align="center">64</td><td align="center">15</td><td></td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">2</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2</td><td align="center">1</td><td></td></tr><tr><td align="left">Ki67 expression</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;Low</td><td align="center">333</td><td align="center">69</td><td align="center">34</td><td align="center">48</td><td align="center">299</td><td align="center">72</td><td></td></tr><tr><td align="left">&#x02003;High</td><td align="center">150</td><td align="center">31</td><td align="center">37</td><td align="center">52</td><td align="center">113</td><td align="center">27</td><td></td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">3</td><td align="center">1</td><td align="center">0</td><td align="center">0</td><td align="center">3</td><td align="center">1</td><td></td></tr></tbody></table></table-wrap><p>Next, immunohistological analyses of EGFR, CK 5/6, and CK14 were performed for all TNBCs available in this study, operated from January 1981 to December 2003. As shown in Table <xref ref-type="table" rid="T2">2</xref>, 31% (33 cases) of TNBC were positive for EGFR protein, 52% (57 cases) expressed CK5/6, and 55% (61 cases) CK14. A total of 77 (70%) had a basal-like phenotype according to Nielsen's definition (TNBC with CK5/6 and/or EGFR expression) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Immunohistochemical Findings in Triple Negative Breast Cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Variables</bold></td><td align="center" colspan="2"><bold>Triple negative (N = 110)</bold></td></tr><tr><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center"><bold><italic>No.</italic></bold></td><td align="center"><bold><italic>%</italic></bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>EGFR</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">69</td><td align="center">62</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">33</td><td align="center">31</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">8</td><td align="center">7</td></tr><tr><td align="left"><bold><italic>Cytokeratin 5/6</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">47</td><td align="center">43</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">57</td><td align="center">52</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left"><bold><italic>Cytokeratin 14</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">43</td><td align="center">40</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">61</td><td align="center">55</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left"><bold><italic>Cytokeratin 5/6/14</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">32</td><td align="center">30</td></tr><tr><td align="left">&#x02003;Posotive</td><td align="center">72</td><td align="center">65</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left"><bold><italic>Basal-like phenotype</italic></bold></td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">24</td><td align="center">22</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">77</td><td align="center">70</td></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">9</td><td align="center">8</td></tr></tbody></table></table-wrap></sec><sec><title>Genomic analysis of <italic>EGFR</italic></title><p>We sought mutations in the <italic>EGFR </italic>gene in TNBCs, because <italic>EGFR </italic>mutations were found in a subset of Japanese non-small lung cancers, despite being very rare in Caucasians [<xref ref-type="bibr" rid="B23">23</xref>], and because these mutations were suggested to predict responses to gefitinib therapy [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. The sequences of primers and probes in TaqMan genotyping assays for the EGFR gene are shown in Table <xref ref-type="table" rid="T3">3</xref>. Genomic DNA was available in 63 of 110 TNBC tissues, and genotyping could be successfully performed for the 14 known <italic>EGFR </italic>mutations in 58 of these. However, none of the 58 TNBC showed any known <italic>EGFR </italic>mutations. We previously reported an increased <italic>EGFR </italic>copy number in a subset of Japanese non-small lung cancers [<xref ref-type="bibr" rid="B18">18</xref>]. As 31% of TNBCs were positive for EGFR protein in this series, we measured <italic>EGFR </italic>gene copy number in 63 TNBCs compared with 42 ER and/or PgR-positive but HER2-negative consecutive breast cancers, (which are also termed luminal subtype [<xref ref-type="bibr" rid="B2">2</xref>]). It was found that 21% (12 cases) of TNBCs contained an increased <italic>EGFR </italic>gene copy number while only one (2%) of luminal subtype tumors showed slightly increased <italic>EGFR </italic>gene copy (Mann-Whitney U-test: <italic>P </italic>= 0.016, Fig. <xref ref-type="fig" rid="F1">1</xref>). We then sought any correlations between the <italic>EGFR </italic>gene copy number and EGFR protein expression based on the immunohistochemical analysis in TNBCs. Only 2 of 14 TNBCs showing EGFR protein expression demonstrated increased <italic>EGFR </italic>gene copy number (Table <xref ref-type="table" rid="T4">4</xref>). There were no significant correlations between these parameters.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Sequence of the mutation-specific TaqMan probes and PCR primers for the <italic>EGFR </italic>gene</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Mutation No.</bold></td><td align="center"><bold>Probe name</bold></td><td align="center"><bold>Nucleotide</bold></td><td align="center"><bold>Amino Acid</bold></td><td align="center"><bold>Primer sequence (forward)</bold></td></tr></thead><tbody><tr><td></td><td align="center">WT1</td><td></td><td></td><td align="center">CCCAGAAGGTGAGAAAGTTAAAATTC</td></tr><tr><td align="center">1</td><td align="center">Del 1a</td><td align="center">2235-2249del</td><td align="center">E746-A750del</td><td align="center">(same as above)</td></tr><tr><td align="center">2</td><td align="center">Del 1b</td><td align="center">2236-2250del</td><td></td><td align="center">(same as above)</td></tr><tr><td align="center">3</td><td align="center">Del 2</td><td align="center">2254-2277del</td><td align="center">S752-I759del</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT2</td><td></td><td></td><td align="center">(same as above)</td></tr><tr><td align="center">4</td><td align="center">Del 3</td><td align="center">2239-2247del, 2248G&#x0003e;C</td><td align="center">L747-E749del, A750P</td><td align="center">(same as above)</td></tr><tr><td align="center">5</td><td align="center">Del 4</td><td align="center">2240-2257del</td><td align="center">L747-S752del, P753S</td><td align="center">(same as above)</td></tr><tr><td align="center">6</td><td align="center">Del 5</td><td align="center">2238-2255del, 2237A&#x0003e;T</td><td align="center">L747-A750del, E746V</td><td align="center">(same as above)</td></tr><tr><td align="center">7</td><td align="center">Del 6</td><td align="center">2240-2251del</td><td align="center">L747-A750del, T747S</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT3</td><td></td><td></td><td align="center">TGAGGATCTTGAAGGAAACTGAATTC</td></tr><tr><td align="center">8</td><td align="center">G719C</td><td align="center">2155G&#x0003e;T</td><td align="center">G719C</td><td align="center">(same as above)</td></tr><tr><td align="center">9</td><td align="center">G719S</td><td align="center">2155G&#x0003e;A</td><td align="center">G719S</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT4</td><td></td><td></td><td align="center">CCGCAGCATGTCAAGATCAC</td></tr><tr><td align="center">10</td><td align="center">L858R</td><td align="center">2573T&#x0003e;G</td><td align="center">L858R</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT5</td><td></td><td></td><td align="center">(same as above)</td></tr><tr><td align="center">11</td><td align="center">L861Q</td><td align="center">2582T&#x0003e;A</td><td align="center">L861Q</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT6</td><td></td><td></td><td align="center">CCCAGAAGGTGAGAAAGTTAAAATTC</td></tr><tr><td align="center">12</td><td align="center">L747Del</td><td align="center">2239-2262del</td><td align="center">L747-K754del</td><td align="center">(same as above)</td></tr><tr><td align="center">13</td><td align="center">N756Ins</td><td align="center">2265-2267InsCAA</td><td align="center">N756Ins</td><td align="center">(same as above)</td></tr><tr><td></td><td align="center">WT7</td><td></td><td></td><td align="center">GGAGGACCGTCGCTTGGT</td></tr><tr><td align="center">14</td><td align="center">L838P</td><td align="center">2513T&#x0003e;C</td><td align="center">L838P</td><td align="center">(same as above)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>TaqMan probe</bold></td><td align="left"><bold>Primer sequence (reverse)</bold></td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">VIC-ATTAAGAGAAGCAACATCT</td><td align="left">CCCACACAGCAAAGCAGAAA</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CGCTATCAAAACATCT</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CTATCAAGACATCTCC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-AGAAGCAACACTCGAT</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-CGAAAGCCAACAAG</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CAAGGAACCAACATC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-AAGGAATCGAAAGCC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CAAGGTTCCGAAAGC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-TCAAGGAATCATCTCC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-AAGTGCTGGGCTCC</td><td align="left">TGCCAGGGACCTTACCTTATACA</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-AAAGTGCTGTGCTCC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-AAAGTGCTGTGCTCC</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-TTGGGCTGGCCAAA</td><td align="left">TCCTTCTGCATGGTATTCTTTCTCT</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-TTGGGCGGGCCAA</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-CCAAACTGCTGGGTG</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CCAAACAGCTGGGTG</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-ATTAAGAGAAGCAACATCT</td><td align="left">CCCACACAGCAAAGCAGAAA</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CTATCAAGGAAGCCAACAA-MGB</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CCAACAACAAGGAAAT-MGB</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr><tr><td align="left">VIC-CGCGACCTGGCAG-MGB</td><td align="left">CCCAAAATCTGTGATCTTGACATG</td><td></td><td></td><td></td></tr><tr><td align="left">FAM-CGCGACCCGGCAG-MGB</td><td align="left">(same as above)</td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p><italic>EGFR </italic>gene copy numbers in breast cancer tissues were estimated with 7500 Fast Real-Time PCR using a QuantiTect SYBR Green Kit (Qiagen Inc, Valencia, CA) as described previously [<xref ref-type="bibr" rid="B18">18</xref>]. Briefly, we have quantified each tumor DNA by comparing the target locus to the reference <italic>Line-1</italic>, a repetitive element for which copy numbers per haploid genome are similar among all normal and neoplastic human cells [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. The relative <italic>EGFR </italic>copy number level was normalized to normal human genomic DNA as the calibrator. Copy number changes relative to the <italic>Line-1 </italic>gene and the calibrator were determined by the formula (T<sub>EGFR</sub>/T<sub>Line-1</sub>)/(C<sub>EGFR</sub>/C<sub>Line-1</sub>), where T<sub>EGFR</sub>/T<sub>Line-1 </sub>are quantity from tumor DNA by using <italic>EGFR </italic>and <italic>Line-1</italic>, and C<sub>EGFR</sub>/C<sub>Line-1 </sub>are quantity from calibrator by using <italic>EGFR </italic>and <italic>Line-1 </italic>[<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Primer sequences for the <italic>EGFR </italic>gene used in this study were: forward, CCACCAAATTAGCCTGGACA; reverse, CGCGACCCTTAGGTATTCTG. <italic>EGFR </italic>gene copy number &#x0003e; 3 was defined as positive [<xref ref-type="bibr" rid="B21">21</xref>].</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Relationship between <italic>EGFR </italic>Copy Number and the Immunohistochemical staining of EGFR protein in Triple Negative Breast Cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Increased EGFR gene copy No.</bold></td><td align="center"><bold>No increased EGFR gene copy No.</bold></td></tr></thead><tbody><tr><td align="center"><bold><italic>EGFR IHC</italic></bold></td><td></td><td></td></tr><tr><td align="center">0</td><td align="center">4</td><td align="center">14</td></tr><tr><td align="center">1</td><td align="center">6</td><td align="center">22</td></tr><tr><td align="center">2</td><td align="center">2</td><td align="center">8</td></tr><tr><td align="center">3</td><td align="center">0</td><td align="center">2</td></tr></tbody></table><table-wrap-foot><p>IHC, immnohistochemistry</p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Epidermal growth factor receptor (<italic>EGFR</italic>) gene copy number in triple-negative and luminal subtypes in Japanese breast cancer patients.</p></caption><graphic xlink:href="1471-2407-8-309-1"/></fig></sec><sec><title><italic>BRCA1 </italic>mRNA expression analysis</title><p>Loss of BRCA1 function has been found in basal-like breast cancer. Therefore, we assessed <italic>BRCA1 </italic>mRNA expression in 61 TNBC and 60 consecutive luminal subtype breast cancers. As shown in Fig. <xref ref-type="fig" rid="F2">2</xref>, <italic>BRCA1 </italic>mRNA expression was significantly decreased in TNBCs compared to luminal subtype breast cancers. <italic>BRCA1 </italic>gene mutations were not analyzed in this study. Therefore, TNBCs in our series may include both <italic>BRCA</italic>1-mutant and sporadic TNBCs. Nonetheless, the fact remains that significantly reduced <italic>BRCA1 </italic>mRNA expression was observed in these Japanese TNBCs.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><italic><bold>BRCA1</bold></italic><bold>mRNA</bold><bold>expression in triple-negative and luminal subtypes in Japanese breast cancer patients</bold>.</p></caption><graphic xlink:href="1471-2407-8-309-2"/></fig></sec><sec><title>Clinical outcome by treatment epoch</title><p>Although adjuvant therapies are effective in breast cancers, their employment was not yet standard practice in Japan in the 1980's. Here, we first compared the outcome for breast cancer patients treated at Nagoya City University Hospital in the 1980's with those treated in the 1990's. All patients treated later tended to show better DDFS compared with those treated in the 1980's (Fig. <xref ref-type="fig" rid="F3">3a</xref>). Patients with tumors of luminal subtype treated in the 1990's showed significantly better DDFS than those from the 1980's (P = 0.02, Fig. <xref ref-type="fig" rid="F3">3b</xref>). In contrast, DDFS of patients with TNBC treated either in the 1980's or 1990's was similar (Fig. <xref ref-type="fig" rid="F3">3c</xref>). Only 58% (61/106 cases) of patients with luminal subtype tumors treated in the 1980's received adjuvant tamoxifen therapy while this figure increased to 78% (194/248 cases) in the 1990's. Therefore, a higher rate of adjuvant hormone therapy might be associated with better DDFS in patients with luminal subtype tumors. For TNBCs, 31% (12/39 cases) treated in the 1980's received chemotherapy (10 patients received oral 5-fluorouracil (5-FU), and 2 were treated with an anthracycline-based regimen) while 38% (12/32 cases) received chemotherapy in the 1990's (11 oral 5-FU, and one CMF (cyclophosphamide/methotrexate/5-FU)-based regimen). Because both the percentage of patients on adjuvant therapy and the adjuvant chemotherapy regimens themselves were similar for TNBC patients in the 1980's and the 1990's, the outcomes in these two treatment epochs were considered to be similar.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Distant disease-free survival (DDFS) according to the treatment epoch.</bold> (a) all patients, (b) luminal subtype breast cancer patients alone, (c) triple-negative breast cancer patients alone.</p></caption><graphic xlink:href="1471-2407-8-309-3"/></fig></sec><sec><title>Clinical outcome according to tumor subtype</title><p>Next, we analyzed the outcome of all patients treated from 1981 to 1999 (n = 531) to compare TNBCs with non-TNBCs. We found that TNBC was not associated with poor DDFS overall (Fig. <xref ref-type="fig" rid="F4">4a</xref>). Non-TNBC were classified into 3 subtypes as follows: 1) luminal subtype (ER+ and/or PgR+ and HER2-), 2) luminal/HER2+ subtype (ER+ and/or PgR+ and HER2+), and 3) HER2+ subtype (ER- and PgR- and HER2+) [<xref ref-type="bibr" rid="B3">3</xref>]. Within 5 years of diagnosis, the Kaplan-Meier survival curves of TNBC and HER2+ subtype patients were similar (Fig. <xref ref-type="fig" rid="F4">4b</xref>). Thereafter, however, the survival curve of TNBCs more closely approximated luminal subtype. DDFS was significantly different between luminal and luminal/HER2+ subtypes (P = 0.0008) but not between TNBC and any other subtype (Fig. <xref ref-type="fig" rid="F4">4b</xref>). For luminal/HER2+ subtype patients, 6 (27%) received no adjuvant therapy and 7 (32%) received adjuvant tamoxifen alone. Therefore, patients with luminal/HER2+ subtype tumor could be considered to have been under-treated in this series.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Distant disease-free survival (DDFS) according to breast cancer subtype.</bold> (a)(b) all patients, (c)(d) node-negative patients alone, (e) node-negative triple-negative breast cancer patients alone.</p></caption><graphic xlink:href="1471-2407-8-309-4"/></fig><p>In our series, 68% of TNBCs were node-negative but only 53% of non-TNBCs (P = 0.02, Table <xref ref-type="table" rid="T1">1</xref>). Therefore, we next analyzed the clinical outcome only in node-negative breast cancers. Fifteen patients (31%) having node-negative TNBC received adjuvant chemotherapy (13 oral 5-FU, and 2 anthracycline-based regimen) while 26 (54%) received no adjuvant therapy. Medical records of 7 patients (15%) having node-negative TNBC were missing. The results show that node-negative TNBC was associated with shorter DDFS than node-negative non-TNBC (Fig. <xref ref-type="fig" rid="F4">4c</xref>). When DDFS of node-negative TNBCs was compared with other subtypes, a significant difference was observed only between TNBC and luminal subtype (Fig. <xref ref-type="fig" rid="F4">4d</xref>). As shown in Fig. <xref ref-type="fig" rid="F4">4e</xref>, grade 1 node-negative TNBCs demonstrated no distant metastasis. However, the number of these patients was very small. Univariate Cox regression analysis indicated that only nodal status was associated with DDFS in TNBCs (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Univariate Cox Regression Analysis of Factors Associated with Distant Disease-free Survival in the Triple-Negative Tumors</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Variables</td><td align="center">P value</td><td align="center">Relative Risk of recurrence (95% CI)</td></tr></thead><tbody><tr><td align="left">Size</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02264;2 cm</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;&#x0003e;2 cm</td><td align="center">0.92</td><td align="center">1.26 (0.44 to 3.65)</td></tr><tr><td align="left">Nodal status</td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">0.02</td><td align="center">2.60 (1.14 to 6.96)</td></tr><tr><td align="left">Grade</td><td></td><td></td></tr><tr><td align="left">&#x02003;1</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;2, 3</td><td align="center">0.22</td><td align="center">2.46 (0.68 to 10.39)</td></tr><tr><td align="left">TP53 expression</td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">0.61</td><td align="center">1.12 (0.72 to 1.77)</td></tr><tr><td align="left">Ki67 expression</td><td></td><td></td></tr><tr><td align="left">&#x02003;Low</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;High</td><td align="center">0.55</td><td align="center">0.88 (1.59 to 1.34)</td></tr><tr><td align="left">EGFR IHC</td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">0.88</td><td align="center">1.07 (0.48 to 2.36)</td></tr><tr><td align="left"><italic>EGFR </italic>gene copy number</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x0003c;3</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;&#x02265;3</td><td align="center">0.2</td><td align="center">0.27 (0.03 to 2.05)</td></tr><tr><td align="left">Cytokeratins</td><td></td><td></td></tr><tr><td align="left">&#x02003;Negative</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;Positive</td><td align="center">0.42</td><td align="center">0.72 (0.33 to 1.68)</td></tr><tr><td align="left">Basal like type</td><td></td><td></td></tr><tr><td align="left">&#x02003;+</td><td></td><td align="center">1.0 (reference)</td></tr><tr><td align="left">&#x02003;-</td><td align="center">0.67</td><td align="center">0.79 (0.34 to 1.80)</td></tr></tbody></table><table-wrap-foot><p>IHC, immunohistochemistry</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>Although adjuvant hormone therapy was shown to be effective for ER-positive breast cancers [<xref ref-type="bibr" rid="B25">25</xref>], and adjuvant trastuzumab therapy was also shown to improve the survival of HER2 positive breast cancers [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>], TNBCs have no targeted therapy at present. We screened TNBCs for 14 known <italic>EGF</italic>R mutations previously reported in lung cancers [<xref ref-type="bibr" rid="B18">18</xref>] but failed to find any. Gefitinib was reported to be effective not only in lung cancers with <italic>EGFR </italic>mutations [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>], but also for lung or colorectal cancers expressing EGFR protein or with increased <italic>EGFR </italic>gene copy number [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. In our study, 31% of TNBCs were found to express EGFR protein, so could be candidates for gefitinib therapy. We also analyzed <italic>EGFR </italic>gene copy numbers of TNBCs by the PCR method [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>], and found frequent increases in TNBCs compared with luminal subtype breast cancers. Although lung cancers having <italic>EGFR </italic>mutations were reported to be responsive to gefitinib therapy, about 10% of lung cancers without <italic>EGFR </italic>mutations were also susceptible to this therapy [<xref ref-type="bibr" rid="B28">28</xref>]. Therefore, even though no <italic>EGFR </italic>mutations were found in TNBCs in this study, TNBCs with increased <italic>EGFR </italic>gene copy number might still be candidates for therapy with anti-EGFR monoclonal antibodies such as gefitinib. We performed FISH assays on representative tumors with increased <italic>EGFR </italic>copy number [<xref ref-type="bibr" rid="B30">30</xref>] but could not compare the PCR and FISH assays. The reason for this was most likely the condition of the paraffin-embedded tissues not being good enough, because we did not see either <italic>EGFR </italic>or <italic>CEP7 </italic>signals as a control (data not shown). In our study, EGFR protein expression was not consistently accompanied by increased <italic>EGFR </italic>gene copy number. One of the reasons for lack of correlation between <italic>EGFR </italic>gene copy number and immunohistochemistry could be the technique used in this study. EGFR protein expression is generally heterogeneous. If a frozen tissue with PCR technique is used, it is subjected to the "dilution effect" and could be responsible for non-correlation in at least some cases. In lung cancers, increased <italic>EGFR </italic>gene copy number was also reported not to be consistently accompanied by positivity for EGFR protein, as assessed by immunohistochemistry [<xref ref-type="bibr" rid="B32">32</xref>]. Although we did not obtain FISH data for TNBCs with increased <italic>EGFR </italic>gene copy numbers, we are confident that the <italic>EGFR </italic>gene copy number data are reliable because the methodology to measure this gene is well-established [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>], and in this series a significant difference in <italic>EGFR </italic>gene copy number was observed between TNBCs and luminal subtype tumors.</p><p>Basal-like breast cancer was reported to frequently possess <italic>BRCA1 </italic>germline mutations [<xref ref-type="bibr" rid="B2">2</xref>], and <italic>BRCA1 </italic>mRNA expression was also shown to be lower in sporadic basal-like breast cancers [<xref ref-type="bibr" rid="B8">8</xref>]. The profound similarities between hereditary <italic>BRCA1</italic>-related breast cancers and basal-like breast cancers suggest a fundamental defect in the <italic>BRCA</italic>1 pathway in sporadic basal-like breast cancers [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Recently, BRCA1 has been demonstrated to play a critical role in the differentiation of ER-negative stem/progenitor cells to ER-positive luminal cells, and it was reported that loss of BRCA1 function resulted in the accumulation of ER-negative stem/progenitor cells, candidates for a cancer stem cell in the basal-like subtype [<xref ref-type="bibr" rid="B35">35</xref>]. BRCA1 was demonstrated to have an important role for DNA double-strand break repair by homologous recombination [<xref ref-type="bibr" rid="B36">36</xref>]. Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks [<xref ref-type="bibr" rid="B37">37</xref>]. Recently, BRCA1/2 dysfunction has been shown to sensitize cells to the inhibition of PARP enzymatic activity [<xref ref-type="bibr" rid="B38">38</xref>]. Therefore, PARP inhibitors may be key drugs for treating TNBCs [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>Although patients with TNBCs were reported to have a poor prognosis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B39">39</xref>], the recurrent pattern of TNBCs was different from non-TNBCs [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. Dent et al [<xref ref-type="bibr" rid="B40">40</xref>] reported that TNBC patients had an increased likelihood of recurrence and death within 5 years of diagnosis but not thereafter, while the recurrent risk among non-TNBCs was shown to be stable over the period of follow-up. Liedtke et al [<xref ref-type="bibr" rid="B41">41</xref>] described the clinical course of 1,118 breast cancer patients who received neoadjuvant chemotherapy. Twenty-three percent of these women had TNBC, and showed an increased likelihood of 3-year progression-free survival and 3-year overall survival [<xref ref-type="bibr" rid="B41">41</xref>]. The clinical course of TNBCs in our series was very similar to these previous reports [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>].</p><p>Patients with TNBC were reported to have increased pathological complete response rates (pCR) to neoadjuvant chemotherapy compared with non-TNBC [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. However, TNBC patients with residual disease after neoadjuvant chemotherapy had worse survival compared with non-TNBC patients [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Carey et al [<xref ref-type="bibr" rid="B43">43</xref>] termed this characteristic of TNBCs "the triple negative paradox". The higher sensitivity to neoadjuvant chemotherapy in TNBCs may suggest that patients with TNBC should be treated more intensively including with novel therapeutic alternatives. In this series, node-negative TNBCs showed poorer prognosis than node-negative non-TNBCs. Node-negative TNBCs could thus be considered to have been under-treated with adjuvant therapy in this series. On the other hand, no recurrence occurred in grade 1 node-negative TNBCs, although this subgroup was very small. This might indicate another issue as to how to classify TNBCs into subgroups that would benefit from more intensive adjuvant therapy. In this study, we did not find any useful prognostic markers of TNBCs although they showed higher positivity for TP53 protein accumulation and higher Ki67 expression.</p></sec><sec><title>Conclusion</title><p>Frequently increased <italic>EGFR </italic>copy number and EGFR protein expression, and decreased <italic>BRCA1 </italic>mRNA expression, were observed in Japanese triple-negative breast cancers. <italic>EGFR </italic>and <italic>BRCA1 </italic>might be candidates for targeted therapies.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>TT conceived and designed the study and drafted the manuscript. NK carried out mRNA expression assay. TT, HY and ST carried out immunohistochemical analysis. KO and HS carried out mutation and amplification assays. HI and YF were involved in data acquisition and interpretation. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/309/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, grant # 19390367.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Whelan</surname><given-names>SL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Teppo</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>DB</given-names></name></person-group><source>Cancer Incidence in Five Continents</source><year>2002</year><publisher-name>Lyon: IARC</publisher-name></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Pesich</surname><given-names>R</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>8418</fpage><lpage>8423</lpage><pub-id pub-id-type="pmid">12829800</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Voduc</surname><given-names>D</given-names></name><name><surname>Bajdik</surname><given-names>C</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Chia</surname><given-names>SK</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name></person-group><article-title>Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="pmid">18316557</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1658</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Hsu</surname><given-names>FD</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Cheang</surname><given-names>M</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Dressler</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5367</fpage><lpage>5374</lpage><pub-id pub-id-type="pmid">15328174</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0220</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>LK</given-names></name><name><surname>Cryns</surname><given-names>VL</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name></person-group><article-title>Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice</article-title><source>Adv Anat Pathol</source><year>2007</year><volume>14</volume><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">18049131</pub-id><pub-id pub-id-type="doi">10.1097/PAP.0b013e3181594733</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rakha</surname><given-names>EA</given-names></name><name><surname>El-Sayed</surname><given-names>ME</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Lee</surname><given-names>AH</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Prognostic markers in triple-negative breast cancer</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17146782</pub-id><pub-id pub-id-type="doi">10.1002/cncr.22381</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Ro</surname><given-names>JY</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Gong</surname><given-names>G</given-names></name></person-group><article-title>Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes</article-title><source>Hum Pathol</source><year>2006</year><volume>37</volume><fpage>1217</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">16938528</pub-id><pub-id pub-id-type="doi">10.1016/j.humpath.2006.04.015</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>NC</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Russell</surname><given-names>AM</given-names></name><name><surname>Springall</surname><given-names>RJ</given-names></name><name><surname>Ryder</surname><given-names>K</given-names></name><name><surname>Steele</surname><given-names>D</given-names></name><name><surname>Savage</surname><given-names>K</given-names></name><name><surname>Gillett</surname><given-names>CE</given-names></name><name><surname>Schmitt</surname><given-names>FC</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Tutt</surname><given-names>AN</given-names></name></person-group><article-title>BRCA1 dysfunction in sporadic basal-like breast cancer</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">17016441</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210014</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>I</given-names></name><name><surname>Yoshimura</surname><given-names>G</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Suzuma</surname><given-names>T</given-names></name><name><surname>Tamaki</surname><given-names>T</given-names></name><name><surname>Umemura</surname><given-names>T</given-names></name><name><surname>Kakudo</surname><given-names>K</given-names></name></person-group><article-title>Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11443609</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(20010701)92:1&#x0003c;54::AID-CNCR1291&#x0003e;3.0.CO;2-8</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matros</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>Lodeiro</surname><given-names>G</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Iglehart</surname><given-names>JD</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name></person-group><article-title>BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>91</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">15868446</pub-id><pub-id pub-id-type="doi">10.1007/s10549-004-7603-8</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up</article-title><source>Histopathology</source><year>1991</year><volume>19</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">1757079</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2559.1991.tb00229.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>JM</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name></person-group><article-title>Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1474</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">10334533</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandioler-Eckersberger</surname><given-names>D</given-names></name><name><surname>Ludwig</surname><given-names>C</given-names></name><name><surname>Rudas</surname><given-names>M</given-names></name><name><surname>Kappel</surname><given-names>S</given-names></name><name><surname>Janschek</surname><given-names>E</given-names></name><name><surname>Wenzel</surname><given-names>C</given-names></name><name><surname>Schlagbauer-Wadl</surname><given-names>H</given-names></name><name><surname>Mittlbock</surname><given-names>M</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Steger</surname><given-names>G</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name></person-group><article-title>TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">10656431</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angele</surname><given-names>S</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Taniere</surname><given-names>P</given-names></name><name><surname>Martel-Planche</surname><given-names>G</given-names></name><name><surname>Vuillaume</surname><given-names>M</given-names></name><name><surname>Bailly</surname><given-names>C</given-names></name><name><surname>Bremond</surname><given-names>A</given-names></name><name><surname>Montesano</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name></person-group><article-title>Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>3536</fpage><lpage>3544</lpage><pub-id pub-id-type="pmid">10999741</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name></person-group><article-title>Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><fpage>R24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">14680497</pub-id><pub-id pub-id-type="doi">10.1186/bcr738</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malzahn</surname><given-names>K</given-names></name><name><surname>Mitze</surname><given-names>M</given-names></name><name><surname>Thoenes</surname><given-names>M</given-names></name><name><surname>Moll</surname><given-names>R</given-names></name></person-group><article-title>Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas</article-title><source>Virchows Arch</source><year>1998</year><volume>433</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">9737789</pub-id><pub-id pub-id-type="doi">10.1007/s004280050226</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Li</surname><given-names>AR</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations</article-title><source>Mod Pathol</source><year>2005</year><volume>18</volume><fpage>1027</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">15920544</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3800438</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Fukai</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay</article-title><source>Lung Cancer</source><year>2005</year><volume>50</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">16199108</pub-id><pub-id pub-id-type="doi">10.1016/j.lungcan.2005.08.009</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Girard</surname><given-names>L</given-names></name><name><surname>Minna</surname><given-names>J</given-names></name><name><surname>Christiani</surname><given-names>D</given-names></name><name><surname>Leo</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>3060</fpage><lpage>3071</lpage><pub-id pub-id-type="pmid">15126342</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3308</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>M</given-names></name><name><surname>Veronese</surname><given-names>S</given-names></name><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Marrapese</surname><given-names>G</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Gambacorta</surname><given-names>M</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name></person-group><article-title>Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study</article-title><source>Lancet Oncol</source><year>2005</year><volume>6</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">15863375</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(05)70102-9</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Ohe</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Tsuta</surname><given-names>K</given-names></name><name><surname>Matsuno</surname><given-names>Y</given-names></name><name><surname>Tateishi</surname><given-names>U</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Nokihara</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Sekine</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>6829</fpage><lpage>6837</lpage><pub-id pub-id-type="pmid">15998907</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.01.0793</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Muzik</surname><given-names>H</given-names></name><name><surname>Saettler</surname><given-names>E</given-names></name><name><surname>Magliocco</surname><given-names>A</given-names></name><name><surname>DiFrancesco</surname><given-names>L</given-names></name><name><surname>Forsyth</surname><given-names>P</given-names></name><name><surname>Garkavtsev</surname><given-names>I</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Riabowol</surname><given-names>K</given-names></name></person-group><article-title>Suppression of ING1 expression in sporadic breast cancer</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>5187</fpage><lpage>5193</lpage><pub-id pub-id-type="pmid">10498868</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1202905</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Tracy</surname><given-names>S</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Kaye</surname><given-names>FJ</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><etal></etal></person-group><article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1497</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">15118125</pub-id><pub-id pub-id-type="doi">10.1126/science.1099314</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Endo</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>A</given-names></name><name><surname>Takada</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><name><surname>Iuchi</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>A</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>2924</fpage><lpage>2929</lpage><pub-id pub-id-type="pmid">15837743</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1904</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><collab>Early Breast Cancer Trialists' Collaborative Group (EBCTCG)</collab></person-group><article-title>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1687</fpage><lpage>1717</lpage><pub-id pub-id-type="pmid">15894097</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66544-0</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Guillaume</surname><given-names>S</given-names></name><name><surname>Feyereislova</surname><given-names>A</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Mariani</surname><given-names>G</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17208639</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60028-2</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romond</surname><given-names>EH</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Tan-Chiu</surname><given-names>E</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>PA</given-names></name><etal></etal></person-group><article-title>Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1673</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">16236738</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa052122</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Endoh</surname><given-names>H</given-names></name><name><surname>Horio</surname><given-names>Y</given-names></name><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Hatooka</surname><given-names>S</given-names></name><name><surname>Shinoda</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name></person-group><article-title>Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2513</fpage><lpage>2520</lpage><pub-id pub-id-type="pmid">15738541</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.00.992</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>FR</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>McCoy</surname><given-names>J</given-names></name><name><surname>Bemis</surname><given-names>L</given-names></name><name><surname>Xavier</surname><given-names>AC</given-names></name><name><surname>Dziadziuszko</surname><given-names>R</given-names></name><name><surname>Gumerlock</surname><given-names>P</given-names></name><name><surname>Chansky</surname><given-names>K</given-names></name><name><surname>West</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">17317677</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdm003</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Endo</surname><given-names>K</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>O</given-names></name><name><surname>Kitahara</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Matsumura</surname><given-names>A</given-names></name><name><surname>Iuchi</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2008</year><volume>134</volume><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">17932690</pub-id><pub-id pub-id-type="doi">10.1007/s00432-007-0320-z</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Lespagnard</surname><given-names>L</given-names></name><name><surname>Durbecq</surname><given-names>V</given-names></name><name><surname>Paesmans</surname><given-names>M</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Gomez-Galdon</surname><given-names>M</given-names></name><name><surname>Veys</surname><given-names>I</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Di Leo</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>4393</fpage><lpage>4399</lpage><pub-id pub-id-type="pmid">15958623</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2256</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinter</surname><given-names>F</given-names></name><name><surname>Papay</surname><given-names>J</given-names></name><name><surname>Almasi</surname><given-names>A</given-names></name><name><surname>Sapi</surname><given-names>Z</given-names></name><name><surname>Szabo</surname><given-names>E</given-names></name><name><surname>Kanya</surname><given-names>M</given-names></name><name><surname>Tamasi</surname><given-names>A</given-names></name><name><surname>Jori</surname><given-names>B</given-names></name><name><surname>Varkondi</surname><given-names>E</given-names></name><name><surname>Moldvay</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry</article-title><source>J Mol Diagn</source><year>2008</year><volume>10</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">18258923</pub-id><pub-id pub-id-type="doi">10.2353/jmoldx.2008.070125</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rakha</surname><given-names>EA</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Basal-like breast cancer: a critical review</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2568</fpage><lpage>2581</lpage><pub-id pub-id-type="pmid">18487574</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2007.13.1748</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Hallmarks of 'BRCAness' in sporadic cancers</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>814</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">15510162</pub-id><pub-id pub-id-type="doi">10.1038/nrc1457</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><name><surname>Foco</surname><given-names>H</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name><name><surname>Merajver</surname><given-names>SD</given-names></name><name><surname>Dontu</surname><given-names>G</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name></person-group><article-title>BRCA1 regulates human mammary stem/progenitor cell fate</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>1680</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">18230721</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0711613105</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name></person-group><article-title>BRCA1 and BRCA2: 1994 and beyond</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>665</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">15343273</pub-id><pub-id pub-id-type="doi">10.1038/nrc1431</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>V</given-names></name><name><surname>Dantzer</surname><given-names>F</given-names></name><name><surname>Ame</surname><given-names>JC</given-names></name><name><surname>de Murcia</surname><given-names>G</given-names></name></person-group><article-title>Poly(ADP-ribose): novel functions for an old molecule</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><fpage>517</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">16829982</pub-id><pub-id pub-id-type="doi">10.1038/nrm1963</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>H</given-names></name><name><surname>McCabe</surname><given-names>N</given-names></name><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Tutt</surname><given-names>AN</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Richardson</surname><given-names>TB</given-names></name><name><surname>Santarosa</surname><given-names>M</given-names></name><name><surname>Dillon</surname><given-names>KJ</given-names></name><name><surname>Hickson</surname><given-names>I</given-names></name><name><surname>Knights</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">15829967</pub-id><pub-id pub-id-type="doi">10.1038/nature03445</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haffty</surname><given-names>BG</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Reiss</surname><given-names>M</given-names></name><name><surname>Kearney</surname><given-names>T</given-names></name><name><surname>Higgins</surname><given-names>SA</given-names></name><name><surname>Weidhaas</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Hait</surname><given-names>W</given-names></name><name><surname>Toppmeyer</surname><given-names>D</given-names></name></person-group><article-title>Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5652</fpage><lpage>5657</lpage><pub-id pub-id-type="pmid">17116942</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.06.5664</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname><given-names>R</given-names></name><name><surname>Trudeau</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Hanna</surname><given-names>WM</given-names></name><name><surname>Kahn</surname><given-names>HK</given-names></name><name><surname>Sawka</surname><given-names>CA</given-names></name><name><surname>Lickley</surname><given-names>LA</given-names></name><name><surname>Rawlinson</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name></person-group><article-title>Triple-negative breast cancer: clinical features and patterns of recurrence</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4429</fpage><lpage>4434</lpage><pub-id pub-id-type="pmid">17671126</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-3045</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>C</given-names></name><name><surname>Mazouni</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Andre</surname><given-names>F</given-names></name><name><surname>Tordai</surname><given-names>A</given-names></name><name><surname>Mejia</surname><given-names>JA</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Hennessy</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1275</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">18250347</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2007.14.4147</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tischkowitz</surname><given-names>M</given-names></name><name><surname>Brunet</surname><given-names>JS</given-names></name><name><surname>Begin</surname><given-names>LR</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name></person-group><article-title>Use of immunohistochemical markers can refine prognosis in triple negative breast cancer</article-title><source>BMC Cancer</source><year>2007</year><volume>7</volume><fpage>134</fpage><pub-id pub-id-type="pmid">17650314</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-7-134</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name><name><surname>Sawyer</surname><given-names>L</given-names></name><name><surname>Gatti</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>DT</given-names></name><name><surname>Collichio</surname><given-names>F</given-names></name><name><surname>Ollila</surname><given-names>DW</given-names></name><name><surname>Sartor</surname><given-names>CI</given-names></name><name><surname>Graham</surname><given-names>ML</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>2329</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">17438091</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1109</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rouzier</surname><given-names>R</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Stec</surname><given-names>J</given-names></name><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Breast cancer molecular subtypes respond differently to preoperative chemotherapy</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>5678</fpage><lpage>5685</lpage><pub-id pub-id-type="pmid">16115903</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2421</pub-id></citation></ref></ref-list></back></article> 